LivaNova (NASDAQ:LIVN) Shares Cross Above Fifty Day Moving Average – Here’s Why

LivaNova PLC (NASDAQ:LIVN)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $80.61 and traded as high as $80.77. LivaNova shares last traded at $80.32, with a volume of 465,952 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have commented on LIVN shares. Weiss Ratings upgraded LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Needham & Company LLC boosted their price target on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. KeyCorp upped their price objective on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Finally, Barclays upped their target price on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $83.50.

LivaNova Trading Up 0.4%

The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The business’s fifty day moving average is $80.61 and its 200-day moving average is $72.35. The stock has a market capitalization of $4.43 billion, a PE ratio of 23.76 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. During the same quarter last year, the business earned $1.05 EPS. LivaNova’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, analysts anticipate that LivaNova PLC will post 3.77 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in LivaNova during the second quarter worth about $4,053,000. California State Teachers Retirement System lifted its stake in shares of LivaNova by 7,996.3% in the 2nd quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company’s stock valued at $423,855,000 after purchasing an additional 5,090,840 shares in the last quarter. Turner Financial Group Inc. purchased a new stake in shares of LivaNova during the 2nd quarter worth about $392,000. Public Employees Retirement System of Ohio purchased a new stake in shares of LivaNova during the 2nd quarter worth about $37,000. Finally, GAMMA Investing LLC increased its position in LivaNova by 18.2% during the 2nd quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock worth $151,000 after purchasing an additional 283 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.